NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $165 million versus the consensus estimate of $161.82 million.

GUIDANCE:

NeoGenomics sees FY2024 revenue of $655-667 million, versus the consensus of $655.6 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.